Latest Documents


  • 8-December-2014

    English, PDF, 726kb

  • 3-December-2014

    English

    Genotoxicity of Manufactured Nanomaterials : Report of the OECD expert meeting

    This report includes the conclusions and recommendations of an expert workshop on the genotoxicity of nanomaterials, which was organized by OECD’s Working Party on Manufactured Nanomaterials. The main topic was the applicability of existing OECD Test Guidelines (TG) for chemical safety to nanomaterials.

    Related Documents
  • 14-November-2014

    English

    Guidance document on elements of a Pollutant Release and Transfer Registers (PRTR): Part 1

    OECD countries have developed PRTR system to track releases and transfers of potentially harmful chemicals. To improve PRTR system, OECD have analysed common elements (pollutants, sectors) in different PRTR systems, mainly focus on institutional arrangement. This serves as a common framework for different PRTR system, and supporting materials for a country that intends to develop or update its PRTR.

    Related Documents
  • 14-November-2014

    English

    Global Pollutant Release and Transfer Register (PRTR): Proposal for a harmonised list of pollutant

    PRTR have been established throughout the world to track releases and transfers of potentially harmful chemicals. But most of the PRTR systems were designed without considering comparability, each PRTR has its own requirement of reporting chemicals and sectors. To harmonise globally, OECD reviewed the reporting chemicals and sectors across PRTR systems and produced proposal for harmonised lists of reporting pollutants.

    Related Documents
  • 20-October-2014

    English

    OECD encourages the development of non-animal test methods for the detection of thyroid disrupters

    The OECD Advisory Group on Endocrine Disrupters Testing and Assessment met on 16-17 October 2014 in Paris to discuss the development and update of Test Guidelines and related documents for endocrine disrupters testing and assessment.

    Related Documents
  • 2-October-2014

    English

    Report of the pilot exercise on classifications for selected chemicals assessed at CoCAM

    The OECD has published a report on a pilot chemical classification exercise undertaken in 2013 and ‘14. Using a number of chemical assessments agreed in the OECD hazard assessment programme, reasons why classification proposals may differ were investigated. The report concludes on the main reasons for such differences, and recommends some measures to overcome some of them.

    Related Documents
  • 29-September-2014

    English

    New, updated and corrected OECD Test Guidelines for the testing of chemicals – 26 September 2014

    On 26 September 2014, the OECD Council adopted three new, five updated and one corrected OECD Test Guidelines for the testing of chemicals.

    Related Documents
  • 26-September-2014

    English

    Test No. 475: Mammalian Bone Marrow Chromosomal Aberration Test

    The mammalian in vivo chromosome aberration test is used for the detection of structural chromosome aberrations induced by test compounds in bone marrow cells of animals, usually rodents (rats, mice and Chinese hamsters). Structural chromosome aberrations may be of two types: chromosome or chromatid.

    Animals are exposed to the test substance (liquid or solid) by an appropriate route of exposure (usually by gavage using a stomach tube or a suitable intubation cannula, or by intraperitoneal injection) and are sacrificed at appropriate times after treatment. Prior to sacrifice, animals are treated with a metaphase-arresting agent. Chromosome preparations are then made from the bone marrow cells and stained, and metaphase cells are analysed for chromosome aberrations. Each treated and control group must include at least 5 analysable animals per sex. The limit dose is 2000 mg/kg/body weight/day for treatment up to 14 days, and 1000 mg/kg/body weight/day for treatment longer than 14 days.

  • 26-September-2014

    English

    Test No. 473: In Vitro Mammalian Chromosomal Aberration Test

    The purpose of the in vitro chromosome aberration test is to identify agents that cause structural chromosome aberrations in cultured mammalian somatic cells. Structural aberrations may be of two types: chromosome or chromatid.

    The in vitro chromosome aberration test may employ cultures of established cell lines, cell strains or primary cell cultures. Cell cultures are exposed to the test substance (liquid or solid) both with and without metabolic activation during about 1.5 normal cell cycle lengths. At least three analysable concentrations of the test substance should be used. At each concentration duplicate cultures should normally be used. At predetermined intervals after exposure of cell cultures to the test substance, the cells are treated with a metaphase-arresting substance, harvested, stained. Metaphase cells are analysed microscopically for the presence of chromosome aberrations.

  • 26-September-2014

    English

    Test No. 474: Mammalian Erythrocyte Micronucleus Test

    The mammalian in vivo micronucleus test is used for the detection of damage induced by the test substance to the chromosomes or the mitotic apparatus of erythroblasts, by analysis of erythrocytes as sampled in bone marrow and/or peripheral blood cells of animals, usually rodents (mice or rats).

    The purpose of the micronucleus test is to identify substances (liquid or solid) that cause cytogenetic damage which results in the formation of micronuclei containing lagging chromosome fragments or whole chromosomes. An increase in the frequency of micronucleated polychromatic erythrocytes in treated animals is an indication of induced chromosome damage. Animals are exposed to the test substance by an appropriate route (usually by gavage using a stomach tube or a suitable intubation cannula, or by intraperitoneal injection). Bone marrow and/or blood cells are collected, prepared and stained. Preparations are analyzed for the presence of micronuclei. Each treated and control group must include at least 5 analysable animals per sex. Administration of the treatments consists of a single dose of test substance or two daily doses (or more). The limit dose is 2000 mg/kg/body weight/day for treatment up to 14 days, and 1000 mg/kg/body weight/day for treatment longer than 14 days.

  • << < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 > >>